Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Dechra Pharmaceuticals PLC

Dalan Animal Health develops and provides a vaccine for honeybees designed to protect them from American Foulbrood. The vaccine is delivered orally to Queen Bees, ensuring the health of the hive through preventative measures. Self-described as pioneers in invertebrate health, Dalan seeks to create sustainable solutions for beekeeping.

Dalan Animal Health

IDEXX provides diagnostic and software products and services for pet healthcare, self-described as a global leader in veterinary innovation.

David Evans Shaw

IDEXX

Vetigenics is focused on advancing targeted antibody-based therapies for pets with cancer and other chronic diseases. The company aims to transform personalized healthcare for pets while supporting advancements in human medicine, based on its proprietary CANIBODY™ platform.

Vetigenics

Dechra is a global specialist in veterinary pharmaceuticals and related products business, engaged in the development, manufacture, marketing, and sales of high-quality products exclusively for veterinarians worldwide.

Metric
Company Name	Dechra Pharmaceuticals PLC	Dalan Animal Health	IDEXX	Vetigenics
Symbol	DPH
MSH ID	COM:DECHRA	COM:DALAN	COM:IDEXX	COM:VETIGENICS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Animal Health	Veterinary Care	Biotechnology
Country	GB	US	US	US
Stage
Employee Count	2.46K		7.37K
Website	dechra.com	dalan.com	idexx.com	vetigenics.com
LinkedIn
Founders

Metric
Market Cap	56.12M
Enterprise Value
Monthly Web Traffic		253.55K
Web Traffic Growth		-0.32
Valuation
Raised Capital

Metric
Revenue	970.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit	543.20M
EBITDA	125.00M
Operating Income	8.03M
Net Income	-35.55M
EPS	-0.32
Diluted EPS	-0.31
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.56
Operating Profit Margin	0.02
EBITDA Margin	0.13
Net Profit Margin	-0.04
Return on Equity	-0.03
Return on Assets	-0.02
Return on Capital Employed	0.01

COM:DECHRA

Dechra

Last Close

3,864.00

15/01 17:38

Market Cap

44.04M

Beta: -

Volume Today

192.11K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-157.74
P/B Ratio	5.83
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.78
EV Multiple	63.88

Metric
Days Sales Outstanding
Days Payables Outstanding	158.91
Days Inventory Outstanding	238.97
Operating Cycle	308.09
Cash Conversion Cycle	149.18
Asset Turnover	0.49

Metric
Operating Cash Flow	81.04M
Free Cash Flow	42.43M
Cash Flow to Debt	0.13
Operating Cash Flow/Sales	0.08
Free Cash Flow Yield	0.01

Metric
Cash & Equivalents	94.80M
Accounts Receivable	-27.40M
Inventory	276.89M
Goodwill	426.23M
Debt to Capitalization	0.40
Debt to Assets	0.32
Current Ratio	2.85
Quick Ratio	1.33

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.00
R&D to Revenue	0.12
SG&A to Revenue